PGP9.5 (Gracile Axonal Dystrophy, Neuron Cytoplasmic Protein 9.5, Park5, Parkinson Disease 5, PGP95, Protein Gene Product 9.5, Ubiquitin Carboxyl-terminal Esterase L1, Ubiquitin Carboxyl-terminal Hydrolase Isozyme L1, Ubiquitin Thioesterase L1, Ubiquitin Thiolesterase L1, UchL1) (HRP)

This MAb reacts with a protein of 20-30kD, identified as PGP9.5, also known as ubiquitin carboxyl-terminal hydrolase-1 (UchL1). Initially, PGP9.5 expression in normal tissues was reported in neurons and neuroendocrine cells but later it was found in distal renal tubular epithelium, spermatogonia, Leydig cells, oocytes, melanocytes, prostatic secretory epithelium, ejaculatory duct cells, epididymis, mammary epithelial cells, Merkel cells, and dermal fibroblasts. Furthermore, immunostaining for PGP9.5 has been shown in a wide variety of mesenchymal neoplasms as well. A mutation in PGP9.5 gene is believed to cause a form of Parkinson's disease.

Applications:
Suitable for use in ELISA, Western Blot, Immunohistochemistry. Other applications not tested.

Recommended Dilution:
Western Blot: 0.5-1ug/ml
Immunohistochemistry: Frozen only
Optimal dilution for a specific application should be determined.

Positive Control:
Cerebellum

Storage and Stability:
Store product at 4°C if to be used immediately within two weeks. For long-term storage, aliquot to avoid repeated freezing and thawing and store at -20°C. Aliquots are stable at -20°C for 12 months after receipt. Dilute required amount only prior to immediate use. Further dilutions can be made in assay buffer. Note: Sodium azide is a potent inhibitor of peroxidase and should not be added to HRP conjugates.
For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.

Note: Applications are based on unconjugated antibody.